Bio-Rad Laboratories (BIO-B) Capital Expenditures (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Capital Expenditures data on file, last reported at $30.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $30.0 million, down 12.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.2 million (down 4.13% YoY), and the FY2025 annual result was $157.6 million, down 4.83% from the prior year.
• Capital Expenditures slipped to $30.0 million in Q1 2026 per BIO-B's latest filing, from $45.8 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $45.8 million in Q4 2025 and troughed at $17.3 million in Q2 2022.
• A 5-year average of $36.6 million and a median of $35.7 million in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 38.04% in 2022, then jumped 99.83% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $34.8 million in 2022, then advanced by 21.41% to $42.3 million in 2023, then grew by 1.5% to $42.9 million in 2024, then gained by 6.76% to $45.8 million in 2025, then sank by 34.5% to $30.0 million in 2026.
• Business Quant data shows BIO-B's Capital Expenditures at $30.0 million in Q1 2026, $45.8 million in Q4 2025, and $31.7 million in Q3 2025.